WeVote

Bill

Bill

HB 292

An Act relating to insurance coverage for pediatric autoimmune neuropsychiatric disorders; and providing for an effective date.

34th Legislature (2025-2026) Introduced by Ashley Carrick and 1 co-sponsor

Requires Alaska insurers to cover treatments for pediatric autoimmune neuropsychiatric disorders (PANS/PANDAS), a diagnosis lacking full medical consensus and potentially raising insurance costs.

(H) COSPONSOR(S): CARRICK
0
WeVote Research Nonpartisan
Bill Summary · HB 292

Legislative bill overview

HB 292 requires insurance coverage for treatment of pediatric autoimmune neuropsychiatric disorders (PANS/PANDAS) in Alaska. The bill mandates that health insurance plans cover recognized medical interventions for these conditions affecting children. It establishes coverage requirements without specifying which treatments must be included or cost-sharing arrangements.

Why is this important

PANS and PANDAS are controversial diagnoses where some medical professionals recognize them as legitimate conditions requiring urgent treatment, while others question their validity and evidence base. Insurance coverage mandates directly affect whether families can access treatments without prohibitive out-of-pocket costs, and may incentivize or discourage certain medical practices. This bill could significantly increase healthcare costs for insurers and potentially affect insurance premiums statewide.

Potential points of contention

  • Medical consensus uncertainty: Major medical organizations (CDC, NIH) have not formally recognized PANS/PANDAS as standard diagnoses, creating debate over whether mandating coverage is appropriate without broader clinical consensus
  • Treatment specification ambiguity: The bill doesn't define which treatments qualify as appropriate coverage, potentially leading to disputes over experimental or high-cost interventions like plasmapheresis or IVIG therapy
  • Insurance cost implications: Mandated coverage requirements typically increase premiums for all policyholders, raising questions about cost-benefit analysis and whether mandatory coverage is the best policy approach

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.